Your browser doesn't support javascript.
loading
T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID.
Visvabharathy, Lavanya; Hanson, Barbara A; Orban, Zachary S; Lim, Patrick H; Palacio, Nicole M; Jimenez, Millenia; Clark, Jeffrey R; Graham, Edith L; Liotta, Eric M; Tachas, George; Penaloza-MacMaster, Pablo; Koralnik, Igor J.
Afiliación
  • Visvabharathy L; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Hanson BA; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Orban ZS; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Lim PH; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Palacio NM; Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Jimenez M; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Clark JR; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Graham EL; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Liotta EM; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Tachas G; Director, Drug Discovery & Patents, Antisense Therapeutics Ltd., Melbourne, Australia.
  • Penaloza-MacMaster P; Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
  • Koralnik IJ; Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA.
medRxiv ; 2022 Oct 21.
Article en En | MEDLINE | ID: mdl-34401886
ABSTRACT
Many people experiencing long COVID syndrome, or post-acute sequelae of SARS-CoV-2 infection (PASC), suffer from debilitating neurologic symptoms (Neuro-PASC). However, whether virus-specific adaptive immunity is affected in Neuro-PASC patients remains poorly understood. We report that Neuro-PASC patients exhibit distinct immunological signatures composed of elevated humoral and cellular responses toward SARS-CoV-2 Nucleocapsid protein at an average of 6 months post-infection compared to healthy COVID convalescents. Neuro-PASC patients also had enhanced virus-specific production of IL-6 from and diminished activation of CD8+ T cells. Furthermore, the severity of cognitive deficits or quality of life disturbances in Neuro-PASC patients were associated with a reduced diversity of effector molecule expression in T cells but elevated IFN-γ production to the C-terminal domain of Nucleocapsid protein. Proteomics analysis showed enhanced plasma immunoregulatory proteins and reduced pro-inflammatory and antiviral response proteins in Neuro-PASC patients compared with healthy COVID convalescents, which were also correlated with worse neurocognitive dysfunction. These data provide new insight into the pathogenesis of long COVID syndrome and a framework for the rational design of predictive biomarkers and therapeutic interventions.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: MedRxiv Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: MedRxiv Año: 2022 Tipo del documento: Article
...